Latest gabapentin Stories
NEWARK, Calif., June 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo Securities 2013 Healthcare Conference at the Intercontinental Hotel in Boston, MA. The presentation at the Wells Fargo conference is scheduled for 11:15 am EDT (8:15 am PDT) on Wednesday, June 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...
NEWARK, Calif., May 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New York City. The presentation at the Jefferies conference is scheduled for 4:30 pm EDT (1:30 pm PDT) on Monday, June 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast...
Improved Safety and Tolerability Compared with Current Therapies is Another Key Market Access Lever for Emerging Neuropathic Pain Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., May 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that expanded labeling for additional neuropathic pain (NP) populations and/or broader NP labeling (peripheral NP) will not...
NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...
NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...
NEWARK, Calif., March 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California. The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 pm EDT) on Tuesday March 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com....
redOrbit Staff & Wire Reports - Your Universe Online A Food and Drug Administration (FDA) advisory committee rejected on Monday two proposed menopause drugs designed to reduce the frequency and severity of hot flashes. In a 12-to-2 vote, the advisory committee for reproductive health drugs voted against approving Depomed’s extended-release gabapentin, known as Sefelsa, which contains a form of an active ingredient used in some anti-seizure medicines. It also rejected in a vote of...
NEWARK, Calif., March 4, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO), a specialty pharmaceutical company, announced today that the Reproductive Health Drugs Advisory Committee (RHDAC) of the U.S. Food and Drug Administration (FDA) voted 2-12 against approval for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin,( )to treat moderate to severe vasomotor symptoms due to menopause. SEFELSA is the proposed trade name for the medication and was formerly...
Advisory Committee of the Food and Drug Administration to Discuss SEFELSA(TM) New Drug Application for the Treatment of Moderate to Severe Vasomotor Symptoms NEWARK, Calif., March 4, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FDA) Reproductive Health Drugs Advisory Committee is meeting this morning to discuss the company's New Drug Application (NDA) for...
NEWARK, Calif., Feb. 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston. The presentation at the Cowen conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, March 5, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...
